News | Cardiovascular Business | January 16, 2018

American College of Cardiology CEO to Lead New Biopharmaceutical Company

Cathy Gates to serve as interim ACC CEO

January 16, 2018 — American College of Cardiology (ACC) Chief Executive Officer Shalom “Shal” Jacobovitz will be leaving the College effective Feb. 2, 2018, to lead CiVi Biopharma Inc., a privately held biopharmaceutical company. Cathy Gates, ACC chief operating officer and executive vice president, will serve as interim CEO.

“There is no doubt that Shal is leaving a legacy that will continue to benefit the College well into the future,” said Mary Norine Walsh, M.D., FACC, ACC president and chair of the board of trustees. “While he will be missed, his leadership over the last several years has ensured the ACC’s overall financial health, operational effectiveness and strategic direction are aligned to meet the needs of our members around the globe.”

Jacobovitz was hired in 2013 to leverage the organizational strengths of the College and to take advantage of opportunities associated with the changing healthcare environment. Since then, Jacobovitz has helped transform the College into a more nimble, strategic, innovative and accountable organization committed to transforming cardiovascular care and improving heart health. Specifically, he has built a culture of staff empowerment and played a key role in working with ACC leaders to transform the College’s governance structure and processes; foster a culture of innovation and continuous learning; and ensure alignment of programs and resources with the College’s strategic plan. Under his leadership the ACC has been recognized among the best places to work by Modern Healthcare.

“It has been a privilege to lead the ACC over the last nearly five years,” Jacobovitz said. “I’m proud of what the College has accomplished during this time and I have no doubt that the Board of Trustees, working with Cathy and the rest of the College’s dedicated staff, will continue to work toward actualizing the vision of a world where innovation and knowledge optimize cardiovascular care and outcomes.”

The ACC will undertake a nationwide search for its next CEO. In the meantime, the board of trustees has appointed Gates as interim CEO.

“With 27 years with the College, the Board and I have the utmost confidence that Cathy will continue to move the College forward,” Walsh said.

For more information: www.acc.org

 


Related Content

News | Cardiovascular Business

July 29, 2024 — Edwards Lifesciences announced investments that reflect the company’s deep commitment to advancing ...

Home July 29, 2024
Home
News | Cardiovascular Business

July 18, 2024 — Circle Cardiovascular Imaging, a developer of artificial intelligence (AI)-driven cardiovascular imaging ...

Home July 18, 2024
Home
News | Cardiovascular Business

July 15, 2024 — Guidehealth, an artificial intelligence (AI)-enabled healthcare services company, has announced a ...

Home July 15, 2024
Home
News | Cardiovascular Business

July 15, 2024 — Edwards Lifesciences announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an ...

Home July 15, 2024
Home
News | Cardiovascular Business

July 11, 2024 — Medical device company R3 Vascular Inc., developer of novel, best-in-class bioresorbable scaffolds for ...

Home July 11, 2024
Home
News | Cardiovascular Business

July 9, 2024 — Disparities in cardiovascular disease outcomes between urban and rural areas continue to widen, yet ...

Home July 09, 2024
Home
Feature | Cardiovascular Business

The DAIC team wishes you a safe and happy 4th of July!

Home July 04, 2024
Home
News | Cardiovascular Business

July 3, 2024 — Over the past decade, 342 cardiology clinics have been acquired by private equity firms, with over 94% of ...

Home July 03, 2024
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

From FDA approvals to new clinical trials, here is a look at DAIC's top-read content during the month of June: 1 ...

Home July 02, 2024
Home
News | Cardiovascular Business

July 1, 2024 — CVRx, Inc., a commercial-stage medical device company, announced three additions to its senior leadership ...

Home July 01, 2024
Home
Subscribe Now